Financial reports
10-K
2023 FY
Annual report
29 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
10-K
2021 FY
Annual report
2 Mar 22
Current reports
8-K
Entry into a Material Definitive Agreement
26 Apr 24
8-K
Other Events
22 Mar 24
8-K
Entry into a Material Definitive Agreement
21 Mar 24
8-K
Annovis Bio Provides Data Announcement Update for the Phase Ii/iii Study of Buntanetap In Alzheimer’s Disease
20 Mar 24
8-K
Other Events
19 Mar 24
8-K
Entry into a Material Definitive Agreement
15 Mar 24
8-K
Annovis Bio Announces Launch of Proposed Public Offering
1 Nov 23
8-K
Other Events
30 Oct 23
8-K
ANNOVIS BIO ANNOUNCES POSITIVE interim INDEPENDENT analysis For STATISTICAL POWER IN its Alzheimer’s study
12 Oct 23
8-K
Amendments to Articles of Incorporation or Bylaws
16 Jun 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
18 Mar 24
424B5
Prospectus supplement for primary offering
18 Mar 24
S-3/A
Shelf registration (amended)
12 Feb 24
S-3
Shelf registration
1 Feb 24
424B5
Prospectus supplement for primary offering
1 Nov 23
424B5
Prospectus supplement for primary offering
30 Oct 23
D
$1.06 mm in equity, sold $1.06 mm, 6 investors
24 Apr 23
424B5
Prospectus supplement for primary offering
31 Mar 23
25
Voluntary exchange delisting
26 Nov 21
8-A12B
Registration of securities on exchange
17 Nov 21
Proxies
DEFA14A
Additional proxy soliciting materials
2 Jun 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
17 Apr 23
DEFA14A
Additional proxy soliciting materials
18 Apr 22
DEF 14A
Definitive proxy
18 Apr 22
DEFA14A
Additional proxy soliciting materials
19 Apr 21
DEF 14A
Definitive proxy
19 Apr 21
DEFA14A
Additional proxy soliciting materials
1 Jun 20
DEF 14A
Definitive proxy
24 Apr 20
Other
EFFECT
Notice of effectiveness
13 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
UPLOAD
Letter from SEC
5 Feb 24
CERT
Certification of approval for exchange listing
17 Nov 21
EFFECT
Notice of effectiveness
12 Feb 21
CORRESP
Correspondence with SEC
9 Feb 21
UPLOAD
Letter from SEC
8 Feb 21
EFFECT
Notice of effectiveness
29 Jan 20
CERT
Certification of approval for exchange listing
28 Jan 20
CORRESP
Correspondence with SEC
24 Jan 20
Ownership
SC 13G/A
HIRSCHMAN ORIN
28 Nov 23
4/A
Mark K. White
22 Nov 23
4/A
Reid McCarthy
22 Nov 23
4/A
Michael B Hoffman
22 Nov 23
4/A
Maria-Luisa Maccecchini
22 Nov 23
4/A
Henry Hagopian III
22 Nov 23
4/A
Claudine Bruck
22 Nov 23
4
Reid McCarthy
21 Nov 23
4
Michael B Hoffman
21 Nov 23
4
Mark K. White
21 Nov 23